Tiago Nava

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6295758/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics Journal, 2022, 22, 9-18.	0.9	1
2	Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study protocol. BMJ Open, 2022, 12, e052131.	0.8	1
3	A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation. BMC Molecular and Cell Biology, 2022, 23, 5.	1.0	1
4	ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	1.3	3
5	Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls. Journal of Pediatric Hematology/Oncology, 2021, 43, e867-e872.	0.3	2
6	The analysis of GSTA1 promoter genetic and functional diversity of human populations. Scientific Reports, 2021, 11, 5038.	1.6	9
7	Genetic Predictors for Sinusoidal Obstruction Syndrome—A Systematic Review. Journal of Personalized Medicine, 2021, 11, 347.	1.1	5
8	Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT. Bone Marrow Transplantation, 2021, 56, 2697-2704.	1.3	2
9	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Pediatrics, 2021, 9, 705179.	0.9	22
10	Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1043-1056.	1.3	13
11	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	4
12	Predictors for participation in DNA self-sampling of childhood cancer survivors in Switzerland. BMC Medical Research Methodology, 2021, 21, 236.	1.4	1
13	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
14	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 1126-1136.	1.3	23
15	The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review. International Journal of Molecular Sciences, 2019, 20, 3889.	1.8	2
16	Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes. Haemophilia, 2019, 25, e113-e117.	1.0	0
17	Incorporation of <i>GSTA1</i> genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. British Journal of Clinical Pharmacology, 2018, 84, 1494-1504.	1.1	25
18	Challenges on the diagnostic approach of inherited platelet function disorders: Is a paradigm change necessary?. Platelets, 2018, 29, 148-155.	1.1	13

Τιάσο Νάνα

#	Article	IF	CITATIONS
19	GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1918-1924.	2.0	16
20	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	0.8	39
21	A Protective Role of DNA Repair Genes Against Acute Graft Versus Host Disease in Children. Blood, 2017, 130, 749-749.	0.6	0
22	Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2016, 128, 665-665.	0.6	0
23	CSTA1 Genotype Influences Performance of Initial Bu Prediction Methods during Conditioning before SCT. Blood, 2015, 126, 4323-4323.	0.6	0
24	CSTA1 *B1a Haplotype Associated with Lower Busulfan Clearance in Conditioning before HSCT in Pediatric Patients. Blood, 2015, 126, 3112-3112.	0.6	1
25	Is It Better to Treat Adolescents with Acute Lymphoblastic Leukemia as Old Children or as Young Adults?. Blood, 2008, 112, 3968-3968.	0.6	2
26	149 Impact of Multiple Births on Low Birth Weight Rate in Porto Alegre, Brazil. Pediatric Research, 2005, 58, 380-380.	1.1	0
27	Barreiras, para a notificação pelo pediatra, de maus-tratos infantis. Revista Brasileira De Saude Materno Infantil, 2005, 5, 103-108.	0.2	21